课题基金 / 基金详情

UCLA-CDU CFAR

UCLA-CDU CFAR
加州大学洛杉矶分校-CDU CFAR
批准号:
10458369
负责人:
Judith S. Currier
金额:
$300.56万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-04-08 至 2027-03-31

项目摘要

项目成果

Judith S. Currier的其他基金

相关文献

中文摘要
翻译
总体:项目摘要/摘要:此应用程序是一个新的CFAR是一个合作伙伴关系的重新提交 加州大学洛杉矶分校和基督教民主联盟之间我们的首要目标是建立一个灵活的多机构基础设施, 促进公平,并将连接和支持与这两个机构有关联的调查人员,以推动关键的艾滋病毒 科学UCLA-CDU CFAR将加强和扩大现有研究活动的影响,并启动 通过我们对三个主题的关注,在洛杉矶和全球范围内建立新的伙伴关系:我们将通过 预防新的艾滋病毒感染(预防),降低艾滋病毒感染者的发病率(治疗), 制定根除战略(无抗逆转录病毒疗法缓解)。这笔赠款将资助与艾滋病有关的活动, 由加州大学洛杉矶分校,基民盟和我们的附属机构,其中包括港口,加州大学洛杉矶分校的研究人员进行的计划, 托兰斯医疗中心;加州大学洛杉矶分校护理诊所和弗吉尼亚州大洛杉矶医疗保健系统, 韦斯特伍德;西好莱坞的加州大学洛杉矶分校藤街诊所;德鲁关怀,基民盟推动联盟和 基督教民主联盟的MLK绿洲诊所这些设施是洛杉矶县艾滋病流行的起点, 居住在我们医院直接服务的社区的艾滋病毒感染者人数最多 和诊所。除了位于洛杉矶的设施和项目外,加州大学洛杉矶分校和基民盟的研究人员还 与地球仪各地旨在建设全球能力的艾滋病毒方案建立广泛的伙伴关系。恒虚警 将通过接触最需要的社区,提高我们在社区界面提供研究的能力 并通过发挥CDU和UCLA研究人员的才能, 在指导下一代更好地反映所服务社区的多样性的同时, 加州大学洛杉矶分校-基民盟CFAR的整体组织将使我们能够有效地管理艾滋病 研究活动,通过利用我们的CFAR中的各种专业知识,并包括与社区的联系, 基于临床研究者和社区。第一年所请求支助的行动计划包括 6个核心和1个科学工作组(SWG):行政核心、发展核心、中央 实验室支持核心,人源化小鼠和基因治疗核心,社区参与和临床 信息学核心,临床科学核心和物质使用转化研究SWG。相关性: 需要研究艾滋病毒疾病的发病机理、治疗和社会方面,以结束这一流行病。 UCLA-CDU CFAR旨在通过提供连接, 支持和提高隶属于加州大学洛杉矶分校和基督教民主联盟的调查人员的能力。这将通过 鼓励开展和传播针对NIH优先事项的高影响力多学科研究 预防新的艾滋病毒感染(预防),降低艾滋病毒感染者的发病率(治疗), 制定根除战略(无抗逆转录病毒疗法缓解)。
英文摘要
Overall: Project Summary/Abstract: This application is a resubmission for a new CFAR that is a partnership between UCLA and CDU. Our overarching goal is to create a nimble multi-institutional infrastructure that promotes equity and will connect and support investigators affiliated with both institutions to advance critical HIV science. The UCLA-CDU CFAR will strengthen and amplify the impact of existing research activities and launch new partnerships across Los Angeles and globally through our focus on three themes: we will STOP HIV by preventing new HIV infections (Prevention), reducing morbidity among people living with HIV (Treatment) and developing strategies for eradication (ART-free Remission). This grant will fund AIDS-related activities and programs conducted by investigators at UCLA, CDU and our Affiliated institutions, which include Harbor-UCLA Medical Center in Torrance; the UCLA CARE Clinic and the VA Greater Los Angeles Healthcare System in Westwood; the UCLA Vine Street Clinic in West Hollywood; and the Drew CARES, the CDU PUSH coalition and the MLK OASIS Clinic at CDU. These facilities are at ground zero for the AIDS epidemic in Los Angeles County, with the greatest number of persons living with HIV residing in the neighborhoods directly served by our hospitals and clinics. In addition to the facilities and programs based in Los Angeles, researchers at UCLA and CDU have extensive partnerships with HIV programs around the globe that are aimed at building global capacity. The CFAR will enhance our ability to deliver research at the interface of community by reaching communities most in need and by bringing to bear the talent of CDU and UCLA researchers to address problems from a multi-disciplinary perspective while mentoring the next generation who better reflect the diversity of communities being served. The overall organization of the UCLA-CDU CFAR will allow us to efficiently and effectively manage AIDS research activities by harnessing the diverse expertise in our CFAR, and by including linkages to community- based clinician investigators and communities. The action plan for the first year of requested support includes 6 cores and 1 scientific working group (SWG): the Administrative Core, Developmental Core, Centralized Laboratory Support Core, Humanized Mouse and Gene Therapy Core, Community Engagement and Clinical Informatics Core, Clinical Science Core, and a Translational Research in Substance Use SWG. RELEVANCE: Research into the pathogenesis, treatment and social aspects of HIV disease is required to end the epidemic. The UCLA-CDU CFAR seeks to catalyze and expand HIV research by providing the infrastructure to connect, support and enhance the capacity of investigators affiliated with UCLA and CDU. This will be accomplished by stimulating the conduct and dissemination of high impact multidisciplinary research aimed at the NIH priorities of preventing new HIV infections (Prevention), reducing morbidity among people living with HIV (Treatment) and developing strategies for eradication (ART-free Remission).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
UCLA-CDU CFAR